ArticleAdvances in radiation oncology2026
Implications for Radiation Microboosting Based on Pathology Correlations With Prostate-Specific Membrane Antigen and Multiparametric Magnetic Resonance Imaging Findings.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography and multiparametric magnetic resonance imaging (mpMRI) are used to contour the dominant intraprostatic lesion (DIL) when incorporating a microboost. However, it is unclear how well PSMA and mpMRI findings correlate with the true pathologic DIL. So, we performed an analysis between preoperative imaging and the final surgical specimen to identify predictors of discordance. Methods and Materials: This was a single-center retrospective analysis of patients with prostate cancer who underwent PSMA imaging before prostatectomy between January 2022 and December 2023. PSMA lesions were independently contoured and measured by a reviewer blinded to the final pathology. mpMRI reports were reviewed for lesion number, location, and size. Lesion size and hemigland location on imaging were compared to the final pathology. Associations between concordance or discordance and patients' demographics and clinicopathological characteristics were examined. Results: Of the 48 patients included, mean (SD) PSA was 13.9 (±12.9), 40% had grade group 4/5 disease, and 58% were staged as pT3 or higher. The pathologic DIL matched the hemigland of the largest PSMA/mpMRI lesion in 94/90% of cases, respectively. The median maximum lesion diameter size discrepancy between PSMA and mpMRI and final pathology was 3.4 mm (IQR, 16.3-24.8) and 4 mm (IQR, 3-9), respectively. PSMA and mpMRI underestimated lesion size in 59% and 64% of cases, respectively. On PSMA, higher prostate-specific antigen (PSA) and lower biopsy grade groups were associated with greater imaging/pathology size discrepancy on both univariate and multivariable analysis after adjusting for maximum standardized uptake volume (SUVmax); on mpMRI, higher PSA was associated with greater imaging/pathology size discrepancy on both univariate and multivariable analysis after adjusting for prostate imaging reporting and data system (PI-RADS) score ( Conclusion: Standard treatment margins may either overestimate or underestimate the extent of the true gross disease, depending on individual tumor characteristics. Further research is needed to develop a standardized framework for using PSMA and mpMRI to guide microboosting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.